PT-141

Mechanism

PT-141, also known as bremelanotide, is the only FDA-approved peptide for treating low sexual desire in women. Unlike medications that work on blood flow, PT-141 works directly in the brain by activating melanocortin receptors involved in sexual arousal and desire. It is used by both men and women for sexual dysfunction, working through a fundamentally different mechanism than PDE5 inhibitors like Viagra.

Effects

## Reproductive/Sexual System — Central Arousal [Tier 1 — FDA-Approved] PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with highest functional activity at MC4R and MC3R. Unlike PDE5 inhibitors (which act peripherally on blood flow), PT-141 acts centrally — it activates MC4R in the medial preoptic area (MPOA) and paraventricular nucleus (PVN) of the hypothalamus, triggering downstream dopaminergic and oxytocinergic pathways that mediate sexual desire and arousal. In women, this manifests as increased subjective arousal, desire, and genital sensitivity. In men, it increases desire and can induce erections via descending signals from the hypothalamus through the spinal cord to sacral parasympathetic outflow. The mechanism is fundamentally different from PDE5 inhibitors: PT-141 increases WANTING (desire, motivation), while Viagra/Cialis increase ABILITY (blood flow). ## Cardiovascular System [Tier 1 — FDA Label Warning] PT-141 causes a transient, dose-dependent increase in blood pressure. At the approved 1.75mg dose, mean systolic BP increases 2-3 mmHg and diastolic 1-2 mmHg, peaking at 2-4 hours post-dose and resolving by 12 hours. At higher doses (tested in early trials), BP increases were more significant. Heart rate decreases slightly (1-3 bpm). This is the basis for the contraindication with PDE5 inhibitors and in uncontrolled cardiovascular disease. ## Gastrointestinal System [Tier 1 — Clinical Trial Data] Nausea is the most common adverse effect, reported by ~40% of women in clinical trials (RECONNECT Phase III) and ~20% of men in earlier studies. The nausea is MC4R-mediated (same mechanism as MT-2 nausea) and peaks 1-2 hours after SC injection. It is self-limiting, lasting 1-4 hours. Approximately 3% of trial participants discontinued due to nausea. ## Integumentary System [Tier 2 — Clinical Data] Unlike MT-2, PT-141 at the approved dose of 1.75mg produces minimal melanogenesis. At higher doses or with repeated use, some users report mild facial flushing and subtle darkening of skin. Hyperpigmentation is listed as a known effect but is uncommon at standard doses. ## Neurological [Tier 2 — Clinical Data] Headache occurs in ~10% of users. Paresthesia (tingling, warmth) reported in ~5%. Hot flashes in ~5%. These are transient and resolve within hours.

Practitioner Guide

## FDA-Approved Indication PT-141 (Vyleesi, AMAG Pharmaceuticals/Palatin Technologies) is FDA-approved (June 2019) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the ONLY on-demand injectable treatment for female sexual dysfunction. ### Dosing for Women (FDA-Approved Protocol) - **Dose:** 1.75 mg SC in the abdomen or thigh - **Timing:** At least 45 minutes before anticipated sexual activity. Peak effect at 1-4 hours. Duration of effect approximately 6-8 hours (some women report effects lasting up to 12-16 hours). - **Frequency limit:** No more than 1 dose per 24 hours, and no more than 8 doses per month (FDA label). The frequency limit is based on melanogenesis concern with repeated MC1R activation. - **Auto-injector:** Vyleesi comes as a pre-filled auto-injector for self-administration. ### Dosing for Men (Off-Label — Widely Used in Sexual Health Clinics) - **Dose range:** 1.0-2.0 mg SC. Most practitioners start at 1.5 mg. Some men respond to doses as low as 0.5 mg. - **Timing:** 2-4 hours before anticipated sexual activity. Men typically report a longer onset time than women. - **Frequency:** Practitioners typically recommend no more than 2-3 times per week, with at least 24 hours between doses. - **Key distinction from PDE5 inhibitors:** PT-141 works on desire/motivation, not mechanics. It is most useful for men with low desire, psychological ED, or SSRI-induced sexual dysfunction. Men with pure vascular ED (who have desire but cannot achieve erection) may benefit more from PDE5 inhibitors alone. - **Off-label compounding:** Many sexual health clinics prescribe compounded bremelanotide for men at doses ranging from 1.0-2.5 mg SC, sometimes as lyophilized powder for reconstitution (much cheaper than Vyleesi auto-injectors). ### Managing Nausea — The #1 Reason Patients Quit Nausea management is CRITICAL to patient retention. Strategies used by experienced sexual health practitioners: 1. **Dose titration:** Start women at 1.0 mg (below the FDA dose) for the first 2-3 uses. Many women get full efficacy at 1.0-1.5 mg with less nausea. Titrate to 1.75 mg only if needed. 2. **Timing:** Inject 3-4 hours before activity rather than the minimum 45 minutes. This allows nausea to peak and resolve before the sexual encounter. 3. **Food:** Light meal 1-2 hours before injection (not immediately before). Avoid heavy or fatty meals. 4. **Anti-emetics:** Ondansetron (Zofran) 4mg ODT 30 minutes before PT-141 injection. This is the single most effective intervention — it reduces nausea incidence from ~40% to ~10% in clinical experience. Ginger capsules (500mg-1g) are a non-prescription alternative. 5. **Positional:** Lying down after injection reduces nausea severity. 6. **Tachyphylaxis:** Like MT-2, nausea often diminishes with repeated use. Many patients who experience nausea on first use report minimal nausea by the 3rd-4th use. 7. **Nasal administration:** Some compounding pharmacies prepare bremelanotide nasal sprays (off-label). Bioavailability is lower and less consistent, but nausea is reported to be significantly less. Typical nasal dose: 2.0-3.0 mg. ### The PDE5 Inhibitor Combination Debate The FDA label explicitly warns against using PT-141 within 24 hours of a PDE5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil). The concern is additive blood pressure effects. However, in the real-world sexual health community, this combination is debated: **The conservative position (FDA label, most guidelines):** Do not combine. The blood pressure interaction is unpredictable. Risk of syncope. Medicolegal liability. **The practitioner reality:** Many sexual health physicians, particularly those treating complex male sexual dysfunction, have observed that the combination addresses both desire (PT-141) and mechanics (PDE5i) and can be transformative for patients with both issues (e.g., SSRI-induced sexual dysfunction with both desire and erectile components). Some practitioners allow the combination under these conditions: - Patient is normotensive at baseline - Low-dose PDE5i (e.g., sildenafil 25mg or tadalafil 5mg daily, not as-needed high doses) - PT-141 dose ≤1.5 mg - Blood pressure monitored at home before and 2 hours after first combined use - Clear patient education about syncope warning signs - Never combine with alcohol **The evidence gap:** There are no published clinical trials studying the combination. The FDA warning is based on pharmacological reasoning (two drugs that both affect blood pressure) rather than clinical outcome data showing harm. ### What Sexual Health Practitioners Actually Observe - **Women with HSDD:** ~50-60% report meaningful improvement in desire. Many describe it as "remembering what it felt like to want sex." The effect is not euphoric or artificial — it restores a sense of natural desire that was absent. Best results in women who previously had normal desire that declined (vs. lifelong low desire). - **Men with desire issues:** Response rates similar to women. Particularly effective for SSRI-induced sexual dysfunction, stress-related low desire, and psychological ED. Less effective for pure vascular ED. - **Onset of action:** Varies significantly between patients. Some feel effects within 30 minutes; others need 3-4 hours. Advise patients to experiment with timing. - **"Non-responders":** About 30-40% of patients do not respond to PT-141. Options include: increasing dose (up to 2.0-2.5 mg off-label), trying nasal administration, or accepting that the patient may have sexual dysfunction etiology not mediated by melanocortin pathways. - **Relationship context matters:** PT-141 increases desire but does not fix relationship dysfunction. Patients with situational desire discrepancy (desire for other partners but not their current partner) may not respond. Screening for relationship factors is important.

Dosing Protocols

Contraindications & Cautions

• hard stop — Uncontrolled hypertension
  PT-141 (bremelanotide) causes transient increases in blood pressure. In patients with uncontrolled hypertension, this may precipitate hypertensive crisis, stroke, or cardiac events. Prescribing information contraindicates use in uncontrolled hypertension.
  Action: Do not use in patients with uncontrolled hypertension (systolic >160 or diastolic >100). Blood pressure must be adequately controlled before initiation.
• hard stop — History of melanoma
  PT-141 acts on melanocortin receptors (MC1R, MC3R, MC4R). Melanocortin receptor activation may promote melanocyte proliferation and has theoretical risk of stimulating melanoma growth or recurrence.
  Action: Do not use in patients with active melanoma or history of melanoma. Patients with numerous atypical nevi or strong family history of melanoma should also avoid use.
• hard stop — Pregnancy
  PT-141 is contraindicated in pregnancy. No adequate safety data. Melanocortin system involvement in reproductive physiology poses theoretical risk.
  Action: Do not use during pregnancy. Verify negative pregnancy test before dosing.
• hard stop — Breastfeeding
  Insufficient data on excretion in breast milk. Melanocortin receptor activation in nursing infant poses unknown risk.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Sexual function peptides are inappropriate for minors.
  Action: Do not provide peptide protocols to individuals under 18.
• hard stop — PDE5 inhibitors
  Concurrent use of PT-141 with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) may cause additive blood pressure reduction and unpredictable cardiovascular effects. Risk of syncope, severe hypotension.
  Action: Do not use PT-141 within 24 hours of PDE5 inhibitor use. This combination is explicitly warned against in bremelanotide prescribing information.
• requires physician — Cardiovascular disease
  PT-141 causes transient blood pressure elevation and may affect heart rate. Patients with known cardiovascular disease, history of MI, heart failure, or arrhythmias are at increased risk of adverse cardiovascular events.
  Action: Requires cardiovascular evaluation before initiation. Monitor blood pressure before and after dosing. Do not use within 24 hours of other vasoactive medications.

Evidence

• Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT (Randomized Efficacy and Safety Study)

  Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA (2019) — Obstetrics & Gynecology — PMID: 31764757

  Bremelanotide 1.75 mg SC as-needed significantly increased sexual desire and reduced distress related to low sexual desire in premenopausal women with HSDD. Mean increase in desire score was statistically significant vs placebo across both replicate trials. Most common side effect was transient nausea (40%) and injection site reactions. Led to FDA approval (Vyleesi) in June 2019.

  strong

• Bremelanotide for Female Hypoactive Sexual Desire Disorder: Integrated Safety Analysis from Phase 3 Clinical Trials

  Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH (2019) — Journal of Women's Health

  Integrated safety analysis of bremelanotide across phase 3 RECONNECT trials confirmed manageable safety profile. Nausea was the most common adverse event (~40%) but was predominantly mild and decreased with repeated use. No significant cardiovascular safety signals at recommended dose. Transient blood pressure increases were small and clinically insignificant. Supported FDA approval for premenopausal HSDD in 2019.

  strong

Stacks featuring this peptide

Research Summary

## Tier 1 — Strong Clinical Evidence - FDA-approved (2019) for HSDD in premenopausal women based on RECONNECT Phase III trials (n=1,247): statistically significant increase in desire (eDiary desire scores) and decrease in distress (FSDS-DAO) vs. placebo - Well-characterized mechanism: MC4R agonism in hypothalamus → dopaminergic/oxytocinergic activation → central sexual arousal - Nausea (~40%), headache (~10%), flushing (~5%), transient BP increase (2-3 mmHg systolic) confirmed across trials - Distinct mechanism from PDE5 inhibitors — acts on desire, not blood flow ## Tier 2 — Moderate Evidence - Efficacy in male sexual dysfunction demonstrated in Phase II studies (erectile function improvement in men with ED, n=342) but not pursued to Phase III approval for men - Off-label use in men widely practiced in sexual health clinics with reported efficacy in desire-related and psychogenic ED - Sub-therapeutic doses (1.0-1.5 mg) may be effective with fewer side effects (clinical experience, no formal dose-ranging in post-approval setting) - Intranasal formulation under investigation for improved tolerability (limited published data) ## Tier 3 — Preclinical/Theoretical - Potential application in SSRI-induced sexual dysfunction (case series support, no RCT) - Possible weight loss effects via MC4R-mediated appetite suppression (observed but not pursued as indication) - Long-term melanogenesis concern with chronic use (theoretical, based on MC1R cross-reactivity) — the 8-dose/month FDA limit is precautionary - Possible application in post-menopausal women (excluded from pivotal trials, no data)